"towards a cure”: hiv reservoirs and strategies to control them

13
"Towards a Cure”: HIV Reservoirs and Strategies to Control Them IAS WORKSHOP, 16 & 17 JULY 2010

Upload: ledung

Post on 28-Jan-2017

219 views

Category:

Documents


4 download

TRANSCRIPT

Page 1: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

"Towards a Cure”:

HIV Reservoirs and Strategies to Control Them

IAS WORKSHOP, 16 & 17 JULY 2010

Page 2: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

HIV-1 Reservoirs and Sanctuary Sites

Satya Dandekar

University of California , Davis

Page 3: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA HAART: Success in HIV Research

•Suppression of viral loads and enhanced immune functions

•Increased life span and clinical benefits

•Prevention of mother-to-child viral transmission

HAART: Challenges

•Viral suppression but not eradication

•Persistence of the viral reservoirs that are latent but have

replication-competent HIV genomes, molecular mechanisms

in operation to suppress viral replication,

•Low level viral replication at tissue anatomic sites despite

HAART

•Incomplete immune recovery

•Incomplete resolution of immune activation

•Reactivation following therapy interruption

Page 4: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA HIV Biology and Early Host-Viral interactions

Page 5: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

Ac u te H I Vr e v is i te d: n e w o p p or t u n i t i e s f ortr e a tm e n t a n d pr e ve n t i o n, P i lc he r e ta lJ. C l in . I n v e s t. 1 1 3: 7 do i: 1 0. 1 1 7 2 /J C I 2 1 5 4 0

ENTRY

SEEDING

DISSEMINATION

HIV-1 Mucosal Transmission and Systemic Dissemination

Primary HIV infection: active viral replication, robust immune

response, cell killing, tissue damage

Page 6: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

Ac u te H I Vr e v is i te d: n e w o p p or t u n i t i e s f ortr e a tm e n t a n d pr e ve n t i o n, P i lc he r e ta lJ. C l in . I n v e s t. 1 1 3: 7 do i: 1 0. 1 1 7 2 /J C I 2 1 5 4 0

ENTRY

few HIV-1 variants transmitted

SEEDING

viral amplification

DISSEMINATION

similar viral population in early infection

viral divergence and compartmentalization in

advanced/chronic HIV infection

HIV-1 Mucosal Transmission and Systemic Dissemination

Page 7: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

Page 8: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA HIV-1 Infection of macrophages and microglia in

Brain

Gonzalez-Scarano et al 2005 Nature Rev Immunol 5:69

Page 9: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

Page 10: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

Questions about HIV reservoirs

1. Is there ongoing residual viral replication in tissue compartments during

HAART? What is the size of latent viral reservoir during HAART? How

does it differ among different tissue compartments?

Despite long term HAART, viral RNA can be detected in gut biopsies

and plasma samples.

2. Will homeostatic proliferation of latently infected cells lead to the

maintenance/expansion of this pool?

During long-term HAART, patients with >60% gut mucosal CD4+ T cell

restoration had suppressed HIV RNA loads but maintained HIV DNA

load.

3. Can the residual viral replication be completely suppressed by HAART

intensification? Is there demonstrable benefit beyond certain thresh-

hold of viral suppression?

4. Better phenotypic characterization of the cells that are latently HIV

infected?

CD16+ monocytes with proinflammatory nature are infected with HIV.

Cell surface markers can be better defined.

Page 11: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA

Homing from periphery

Treg cell

MUCOSA

Th17 cell

IL-10

IL-12

IL-4

Th1 cell

Antigen

loaded DC

Enteric

pathogens

SIV

Luminal

Bacteria

Questions about tissue microenvironment

Page 12: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA Questions about tissue microenvironment

1. Will initiation of HAART early in infection restore CD4+ T cells and anti-

viral functions at the mucosal sites? Will this provide better control of the

immune activation? Will it reduce the burden of latent viral reservoir?

•Initiation of therapy during primary SIV infection led to effective restoration

of gut mucosal CD4+ T cells and anti-viral mucosal T cell responses.

2. Can efforts to accelerate gut mucosal epithelium recovery be beneficial

for mucosal immune response to HIV and other pathogens?

•HIV induced gut mucosal damage may slow epithelium repair and

regeneration.

3. What is the role of gut mucosal innate responses in aiding HIV

suppression?

•Expression of anti-microbial and anti-viral molecules are critical in mucosal

protection. Innate responses are important components of mucosal

immune response.

Page 13: "Towards a Cure”: HIV Reservoirs and Strategies to Control Them

IAS HIV RESERVOIRS W

ORKSHOP, 16 & 17 JULY 2010, VIENNA Utility of the Simian immunodeficiency virus model

Availability of combination therapy for the analysis of viral reservoirs, their

size and locations.

Suitable for evaluating effects of early HAART initiation on viral reservoirs

and anti-viral immune responses in tissue compartments

Valuable for using novel approaches to repair the gut epithelial damage and

evaluate any benefit in preventing microbial translocation and leakage of

microbial products

Appropriate for evaluating early initiation of therapy with therapeutic

vaccines.